⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

April 15, 2024Open Access

Supplementary Figure 5 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer

Harshabad Singh Pranshu Sahgal Kevin S. Kapner Steven M. Corsello Hersh Gupta Rahul Gujrathi Yvonne Li Andrew D. Cherniack Raquelle El Alam Joseph A. Kerfoot Elizabeth Andrews Annette Lee Chetan Nambiar Alison M. Hannigan Joshua Remland Lauren K. Brais Meghan E. Leahy Douglas A. Rubinson Benjamin L. Schlechter Matthew Meyerson Yanan Kuang Cloud P. Paweletz Jessica Lee Júlia C.F. Quintanilha Andrew J. Aguirre Kimberly Perez Brandon M. Huffman Humberto Rossi Thomas A. Abrams Sheheryar Kabraji Livio Trusolino Andrea Bertotti Ewa Sicinska Aparna R. Parikh Brian M. Wolpin Alexa B. Schrock Marios Giannakis Kimmie Ng Jeffrey A. Meyerhardt Jason L. Hornick Nilay S. Sethi James M. Cleary

View Full Paper

Ask AI

Bookmark

Share

Abstract

Supplementary Figure 5. LS180 and SW480 harbor endogenous hotspot mutations in KRAS.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Singh et al. (2024) studied this question.

synapsesocial.com/papers/68e6f2a2b6db64358766d23c https://doi.org/10.1158/1078-0432.25603654

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure 5 from <i>RAS/RAF</i> Comutation and <i>ERBB2</i> Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer2024
2Supplementary Figure 6 from <i>RAS/RAF</i> Comutation and <i>ERBB2</i> Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer2024
3Supplementary Figure 6 from <i>RAS/RAF</i> Comutation and <i>ERBB2</i> Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer2024
4Supplementary Figure 4 from <i>RAS/RAF</i> Comutation and <i>ERBB2</i> Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer2024
5Supplementary Figure 4 from <i>RAS/RAF</i> Comutation and <i>ERBB2</i> Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer2024

Supplementary Figure 2 from <i>RAS/RAF</i> Comutation and <i>ERBB2</i> Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer2024
Supplementary Figure 2 from <i>RAS/RAF</i> Comutation and <i>ERBB2</i> Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer2024
Supplementary Figure 1 from <i>RAS/RAF</i> Comutation and <i>ERBB2</i> Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer2024